{"title":"Impact of androgen deprivation therapy on sexual health in patients who underwent brachytherapy for prostate cancer.","authors":"Kenta Onishi, Yasushi Nakai, Fumisato Maesaka, Mitsuru Tomizawa, Takuto Shimizu, Shunta Hori, Yosuke Morizawa, Daisuke Gotoh, Makito Miyake, Kaori Yamaki, Isao Asakawa, Fumiaki Isohashi, Kiyohide Fujimoto, Nobumichi Tanaka","doi":"10.1111/andr.70066","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Androgen deprivation therapy (ADT) is used in the management of prostate cancer. Post-therapy recovery from the induced hypogonadal state is protracted and correlates with diminished quality of life (QOL).</p><p><strong>Objective: </strong>This study assessed the impact of short-term ADT on sexual health following brachytherapy.</p><p><strong>Materials and methods: </strong>The study included patients administered brachytherapy with or without short-term neoadjuvant ADT (≤6 months) at our institution from 2010 to 2018. Serum total testosterone levels, chronological changes in erectile function, and health-related QOL were evaluated.</p><p><strong>Results: </strong>Of 139 participants, 41 received neoadjuvant ADT (median, 4 months). Sexual health inventory for men (SHIM) scores and sexual function domain of the expanded prostate cancer index composite (EPIC) scores deteriorated significantly up to 36 months post-treatment in patients receiving brachytherapy with neoadjuvant ADT compared to those without. A significant decline was observed in the sexual bother domain of the EPIC scores of patients without neoadjuvant ADT up to 6 months post-treatment relative to those with neoadjuvant ADT. Total testosterone levels in the brachytherapy with neoadjuvant ADT group gradually recovered post-treatment and were similar to those in the brachytherapy without neoadjuvant ADT group after 12-month treatment. Neoadjuvant ADT and a lower pre-treatment SHIM score were risk factors for severe erectile dysfunction 12 months after treatment.</p><p><strong>Discussion: </strong>Restoring sexual health extends beyond the normalization of testosterone levels following cessation of ADT. ADT significantly influences erectile dysfunction after brachytherapy. Our research identified a time lag between the restoration of testosterone levels and the improvement of erectile function and sexual QOL. We hypothesized that individuals undergoing ADT had diminished sexual distress, attributable to fewer opportunities for sexual engagement than their untreated counterparts.</p><p><strong>Conclusion: </strong>Persistent sexual dysfunction occurs despite the normalization of testosterone levels post-ADT. Understanding sexual QOL changes following brachytherapy with ADT will help guide treatment recommendations and patient decision-making.</p>","PeriodicalId":7898,"journal":{"name":"Andrology","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Andrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/andr.70066","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ANDROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Androgen deprivation therapy (ADT) is used in the management of prostate cancer. Post-therapy recovery from the induced hypogonadal state is protracted and correlates with diminished quality of life (QOL).
Objective: This study assessed the impact of short-term ADT on sexual health following brachytherapy.
Materials and methods: The study included patients administered brachytherapy with or without short-term neoadjuvant ADT (≤6 months) at our institution from 2010 to 2018. Serum total testosterone levels, chronological changes in erectile function, and health-related QOL were evaluated.
Results: Of 139 participants, 41 received neoadjuvant ADT (median, 4 months). Sexual health inventory for men (SHIM) scores and sexual function domain of the expanded prostate cancer index composite (EPIC) scores deteriorated significantly up to 36 months post-treatment in patients receiving brachytherapy with neoadjuvant ADT compared to those without. A significant decline was observed in the sexual bother domain of the EPIC scores of patients without neoadjuvant ADT up to 6 months post-treatment relative to those with neoadjuvant ADT. Total testosterone levels in the brachytherapy with neoadjuvant ADT group gradually recovered post-treatment and were similar to those in the brachytherapy without neoadjuvant ADT group after 12-month treatment. Neoadjuvant ADT and a lower pre-treatment SHIM score were risk factors for severe erectile dysfunction 12 months after treatment.
Discussion: Restoring sexual health extends beyond the normalization of testosterone levels following cessation of ADT. ADT significantly influences erectile dysfunction after brachytherapy. Our research identified a time lag between the restoration of testosterone levels and the improvement of erectile function and sexual QOL. We hypothesized that individuals undergoing ADT had diminished sexual distress, attributable to fewer opportunities for sexual engagement than their untreated counterparts.
Conclusion: Persistent sexual dysfunction occurs despite the normalization of testosterone levels post-ADT. Understanding sexual QOL changes following brachytherapy with ADT will help guide treatment recommendations and patient decision-making.
期刊介绍：
Andrology is the study of the male reproductive system and other male gender related health issues. Andrology deals with basic and clinical aspects of the male reproductive system (gonads, endocrine and accessory organs) in all species, including the diagnosis and treatment of medical problems associated with sexual development, infertility, sexual dysfunction, sex hormone action and other urological problems. In medicine, Andrology as a specialty is a recent development, as it had previously been considered a subspecialty of urology or endocrinology
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
